Arovella Therapeutics Limited (AU:ALA) has released an update.
Arovella Therapeutics Ltd. showcased promising data at the AACR Annual Meeting, highlighting the potential of their ALA-101 cell therapy in targeting CD19-positive cancer cells. The therapy leverages diverse subsets of CAR-iNKT cells, including a cytotoxic CD4- population, which are key to its tumor-fighting capabilities. These findings underscore the therapy’s potential and pave the way for upcoming Phase 1 clinical trials.
For further insights into AU:ALA stock, check out TipRanks’ Stock Analysis page.
